Medindia

X

Onyx Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference

Wednesday, March 17, 2010 Corporate News J E 4
Advertisement


EMERYVILLE, Calif., March 16 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through April 6, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing NexavarŽ (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

NexavarŽ (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.

SOURCE Onyx Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Emdeon Reports Fourth Quarter and Full Year 2009 R...
S
Early Identification of Alzheimer's Disease With P...